Home > Insider Trading > Filing (0001012975-20-000664)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1693011	Inozyme Pharma Inc.	INZY	Pharmaceutical Preparations (2834)	475129768

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1695076	Pivotal Bioventure Partners Fund I, L.p.	501 Second Street, Suite 200 San Francisco CA 94107	No	No	Yes	No
1752847	Pivotal Bioventure Partners Fund I U.g.p., Ltd	501 Second Street, Suite 200 Los Angeles CA 94107	No	No	Yes	No
1752862	Pivotal Bioventure Partners Fund I G.p., L.p.	501 Second Street, Suite 200 San Francisco CA 94107	No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2020-07-28	1,403,654	$0.00	1,403,654	No	4	C	Indirect	See footnote
Common Stock	Acquisiton	2020-07-28	187,500	$16.00	1,591,154	No	4	P	Indirect	See footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See footnote
No	4	P	Indirect	See footnote

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A-2 Convertible Preferred Stock	Disposition	2020-07-28	10,489,510	$0.00	1,403,654	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Indirect

Footnotes

On July 28, 2020, the Series A-2 Convertible Preferred Stock automatically converted into Common Stock on a 7.4730-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A-2 Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
The reportable securities are owned directly by Pivotal bioVenture Partners Fund I, L.P. ("Pivotal"). The general partner of Pivotal is Pivotal bioVenture Partners Fund I G.P., L.P. ("Pivotal GP"). The general partner of Pivotal GP is Pivotal bioVenture Partners Fund I U.G.P., Ltd (the "Ultimate General Partner"). Robert Hopfner, Vincent Cheung, Peter Bisgaard, and Heather Preston are the managing partners of Pivotal's investment advisor and may be deemed to have shared voting and dispositive power over the securities owned by Pivotal. Such person's disclaim beneficial ownership over such securities except to the extent of any pecuniary interest therein.